Another phenylketonuria hold, courtesy of Homology

The phenylketonuria pipeline already had one project on clinical hold, and now it has another: Homology Medicines’ HMI-102 on Friday joined Biomarin’s BMN 307 in attracting scrutiny from the FDA. It is not yet clear exactly what the problem is with HMI-102, but Homology cited “elevated liver function tests” in the phase 1/2 Phenix trial.